CancerFree Biotech

Executive Summary

CancerFree Biotech is a Taiwan-based precision oncology company that addresses the critical problem of ineffective cancer treatment selection. Its proprietary E.V.A. Select platform uses patient blood samples to create personalized 'avatar' tumor models for ex vivo drug testing. By testing chemotherapy, hormone therapy, and targeted therapies on these avatars, the platform aims to identify the most effective drug for each patient, reducing the trial-and-error approach and minimizing unnecessary side effects and costs. Founded in 2020, the company has rapidly advanced from R&D to commercial stage, targeting the growing precision oncology market in Asia and beyond. The company operates as a private entity with a lean team of 10-50 employees and has focused on building clinical partnerships to validate and commercialize its technology. With the global precision oncology market expected to exceed $150 billion by 2030, CancerFree Biotech is well-positioned to capture a niche by offering a real-time, patient-specific testing service. Its commercial stage suggests initial traction, but broader adoption depends on securing clinical evidence, regulatory approvals, and strategic collaborations. If successful, E.V.A. Select could become a standard tool for oncologists, improving outcomes and reducing healthcare waste.

Upcoming Catalysts (preview)

• Q2 2026Strategic partnership with a major Asian hospital network for clinical adoption75% success
• Q4 2026Publication of validation study results in a peer-reviewed oncology journal70% success
• Q3 2026Completion of a Series A or B funding round to scale operations60% success